<DOC>
	<DOCNO>NCT00467844</DOCNO>
	<brief_summary>The purpose study ass Gtx-024 effective increase lean body mass subject muscle waste related cancer .</brief_summary>
	<brief_title>Study GTx-024 Muscle Wasting ( Cachexia ) Cancer .</brief_title>
	<detailed_description>Cancer cachexia characterize hypermetabolic state lead catabolism responsible reduction lean mass.These catabolic change accompany increase total energy expenditure , decrease voluntary energy expenditure ultimately result clinically cachexia symptom lethargy , fatigue , weakness general malaise ( Kotler DP . Cachexia . Ann Intern Med . 2000 ; 133:622-634 ) . The prevalence cachexia increase 50 percent presentation 80 percent death malignancy . In 20 percent cancer patient , cachexia cause death ( Bruera E. Anorexia , cachexia nutrition . Br Med J 1997 ; 315:1219-1222 ) . Cancer cachexia lead short survival , decrease response rate increase toxicity chemotherapy , weakness , overall decrease quality life ( DeWys et al . Prognostic effect weight loss prior chemotherapy cancer patient . Eastern Cooperative Oncology Group . Am J Med . 1980 Oct ; 69 ( 4 ) :491-7 ) . The purpose study assess efficacy GTx-024 total body lean mass . Secondary endpoint include limited assessment GTx-024 muscle function , total body weight total body fat mass .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>To eligible participation study , subject must meet following criterion : diagnose Stage 2 , 3 4 nonsmall cell lung cancer Stage 2 , 3 4 colorectal cancer nonhodgkin 's lymphoma chronic lymphocytic leukemia Stage 3 4 breast cancer . prior initiation cycle chemotherapy . experienced great equal 2 % weight loss high patient report weight 6 month prior screen Protocol G200502 ( Wt = body weight ) % weight loss = ( Wt screen high Wt last 6 month ) / high Wt last 6 month x 100 % If surgery part cancer treatment , screen study conduct least 2 week ( 14 day ) surgery . life expectancy &gt; 6 month FEMALES clinically confirm postmenopausal MALES 45 year age ECOG score ≤1 Subjects follow NOT eligible enrollment study : history active/uncontrolled congestive heart failure , chronic hepatitis , hepatic cirrhosis , HIV infection Cardiovascular : No uncontrolled hypertension Positive screen Hepatitis B consist HBsAg ( Hepatitis B Surface Antigen ) , antiHCV ( Hepatitis C Antibody ) , hepatitis A antibody IgM , HIV Currently take testosterone , OXANDRIN® ( oxandrolone ) , testosteronelike agent ( DHEA , androstenedione , androgenic compound , include herbal ) , antiandrogens ( Please note previous therapy testosterone testosteronelike agent acceptable 30 day washout . However , previous testosterone therapy longterm depot , within past 6 month , site call medical monitor study determine appropriate washout period . ) Currently take megestrol acetate ( MEGACE® ) , dronabinol ( MARINOL® ) , prescription medication intend increase appetite treat unintentional weight loss</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cachexia</keyword>
	<keyword>Muscle Wasting</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Stage 3 4 Breast Cancer</keyword>
	<keyword>Chronis Lymphocytic Leukemia</keyword>
</DOC>